Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models

School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 01/2011; 71(1):72-87. DOI: 10.1111/j.1365-2125.2010.03799.x
Source: PubMed

ABSTRACT The prediction of drug-drug interactions (DDIs) from in vitro data usually utilizes an average dosing interval estimate of inhibitor concentration in an equation-based static model. Simcyp®, a population-based ADME simulator, is becoming widely used for the prediction of DDIs and has the ability to incorporate the time-course of inhibitor concentration and hence generate a temporal profile of the inhibition process within a dynamic model.
Prediction of DDIs for 35 clinical studies incorporating a representative range of drug-drug interactions, with multiple studies across different inhibitors and victim drugs. Assessment of whether the inclusion of the time course of inhibition in the dynamic model improves prediction in comparison with the static model. Investigation of the impact of different inhibitor and victim drug parameters on DDI prediction accuracy including dosing time and the inclusion of active metabolites. Assessment of ability of the dynamic model to predict inter-individual variability in the DDI magnitude.
Static and dynamic models (incorporating the time course of the inhibitor) were assessed for their ability to predict drug-drug interactions (DDIs) using a population-based ADME simulator (Simcyp®V8). The impact of active metabolites, dosing time and the ability to predict inter-individual variability in DDI magnitude were investigated using the dynamic model.
Thirty-five in vivo DDIs involving azole inhibitors and benzodiazepines were predicted using the static and dynamic model; both models were employed within Simcyp for consistency in parameters. Simulations comprised of 10 trials with matching population demographics and dosage regimen to the in vivo studies. Predictive utility of the static and dynamic model was assessed relative to the inhibitor or victim drug investigated.
Use of the dynamic and static models resulted in comparable prediction success, with 71 and 77% of DDIs predicted within two-fold, respectively. Over 40% of strong DDIs (>five-fold AUC increase) were under-predicted by both models. Incorporation of the itraconazole metabolite into the dynamic model resulted in increased prediction accuracy of strong DDIs (80% within two-fold). Bias and imprecision in prediction of triazolam DDIs were higher in comparison with midazolam and alprazolam; >50% of triazolam DDIs were under-predicted regardless of the model used. Predicted inter-individual variability in the AUC ratio (coefficient of variation of 45%) was consistent with the observed variability (50%).
High prediction accuracy was observed using both the Simcyp dynamic and static models. The differences observed with the dose staggering and the incorporation of active metabolite highlight the importance of these variables in DDI prediction.

Download full-text


Available from: Geoffrey T Tucker, Jul 27, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prediction of in vivo drug-drug interactions (DDIs) from in vitro and in vivo data, also named in vitro in vivo extrapolation (IVIVE), is of interest to scientists involved in the discovery and development of drugs. To avoid detrimental DDIs in humans, new drug candidates should be evaluated for their possible interaction with other drugs as soon as possible, not only as an inhibitor or inducer (perpetrator) but also as a substrate (victim). DDI risk assessment is addressed along the drug development program through an iterative process as the features of the new compound entity are revealed. Both in vitro and preclinical/clinical outcomes are taken into account to better understand the behavior of the developed compound and to refine DDI predictions. During the last decades, several equations have been proposed in the literature to predict DDIs, from a quantitative point of view, showing a substantial improvement in the ability to predict metabolism-based in vivo DDIs. Mechanistic and dynamic approaches have been proposed to predict the magnitude of metabolic-based DDIs. The purpose of this article is to provide an overview of the current equations and methods, the pros and cons of each method, the required input data for each of them, as well as the mechanisms (i.e., reversible inhibition, mechanism-based inhibition, induction) underlying metabolic-based DDIs. In particular, this review outlines how the methods (static and dynamic) can be used in a complementary manner during drug development. The discussion of the limitations and advantages associated with the various approaches, as well as regulatory requirements in that field, can give the reader a helpful overview of this growing area.
    Drug metabolism and drug interactions 01/2011; 26(4):147-68. DOI:10.1515/DMDI.2011.031
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early prediction of human pharmacokinetics (PK) and drug-drug interactions (DDI) in drug discovery and development allows for more informed decision making. Physiologically based pharmacokinetic (PBPK) modelling can be used to answer a number of questions throughout the process of drug discovery and development and is thus becoming a very popular tool. PBPK models provide the opportunity to integrate key input parameters from different sources to not only estimate PK parameters and plasma concentration-time profiles, but also to gain mechanistic insight into compound properties. Using examples from the literature and our own company, we have shown how PBPK techniques can be utilized through the stages of drug discovery and development to increase efficiency, reduce the need for animal studies, replace clinical trials and to increase PK understanding. Given the mechanistic nature of these models, the future use of PBPK modelling in drug discovery and development is promising, however, some limitations need to be addressed to realize its application and utility more broadly.
    Xenobiotica 01/2012; 42(1):94-106. DOI:10.3109/00498254.2011.627477 · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Predictions of drug-drug interactions (DDIs) are commonly performed for single inhibitors, but interactions involving multiple inhibitors also frequently occur. Predictions of such interactions involving stereoisomer pairs, parent/metabolite combinations and simultaneously administered multiple inhibitors are increasing in importance. This review provides the framework for predicting inhibitory DDIs of multiple inhibitors with any combination of reversible inhibition mechanism. AREAS COVERED: The review provides an overview of the reliability of the in vitro determined reversible inhibition mechanism. Furthermore, the article provides a method to predict DDIs for multiple reversible inhibitors that allows substituting the inhibition constant (K(i)) with an inhibitor affinity (IC(50)) value determined at S < K(M). EXPERT OPINION: A better understanding and the prediction methods of DDIs, resulting from multiple inhibitors, are important. The inhibition mechanism of a reversible inhibitor is often equivocal across studies and unreliable. Determination of the K(i) requires the assignment of reversible inhibition mechanism but in vitro-to-in vivo prediction of DDI risk can be achieved for multiple inhibitors from estimates of the inhibitor affinity (IC(50)) only, regardless of the inhibition mechanism.
    Expert Opinion on Drug Metabolism &amp Toxicology 03/2012; 8(4):449-66. DOI:10.1517/17425255.2012.667801 · 2.93 Impact Factor
Show more